Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Free Tissue Flaps | 7 | 2024 | 59 | 2.360 |
Why?
|
| Mandibular Reconstruction | 2 | 2024 | 8 | 1.590 |
Why?
|
| Head and Neck Neoplasms | 11 | 2024 | 699 | 1.160 |
Why?
|
| Laryngeal Neoplasms | 4 | 2023 | 104 | 1.120 |
Why?
|
| Osteoradionecrosis | 2 | 2023 | 17 | 1.020 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 283 | 0.950 |
Why?
|
| Tongue Neoplasms | 2 | 2023 | 30 | 0.930 |
Why?
|
| Mandibular Osteotomy | 1 | 2024 | 6 | 0.900 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2023 | 874 | 0.890 |
Why?
|
| Veterans | 5 | 2023 | 1761 | 0.870 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2021 | 30 | 0.840 |
Why?
|
| Pregnancy Tests | 1 | 2023 | 2 | 0.820 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 24 | 0.810 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 115 | 0.740 |
Why?
|
| Scapula | 1 | 2021 | 15 | 0.710 |
Why?
|
| Cephalometry | 1 | 2021 | 35 | 0.700 |
Why?
|
| Mouth | 1 | 2021 | 72 | 0.690 |
Why?
|
| Veterans Health | 1 | 2021 | 179 | 0.650 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 1386 | 0.640 |
Why?
|
| Minority Groups | 1 | 2020 | 255 | 0.570 |
Why?
|
| Postoperative Complications | 4 | 2024 | 3226 | 0.460 |
Why?
|
| Mandible | 3 | 2024 | 82 | 0.460 |
Why?
|
| Prostatic Neoplasms | 5 | 2024 | 1623 | 0.450 |
Why?
|
| Laryngectomy | 3 | 2023 | 34 | 0.400 |
Why?
|
| Prostatectomy | 5 | 2024 | 357 | 0.390 |
Why?
|
| Retrospective Studies | 18 | 2024 | 17481 | 0.360 |
Why?
|
| Middle Aged | 18 | 2024 | 29394 | 0.320 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1315 | 0.300 |
Why?
|
| Aged | 13 | 2024 | 21730 | 0.280 |
Why?
|
| Graft Survival | 2 | 2021 | 558 | 0.260 |
Why?
|
| Disease-Free Survival | 4 | 2020 | 971 | 0.250 |
Why?
|
| Humans | 32 | 2024 | 133931 | 0.240 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 398 | 0.230 |
Why?
|
| Mandibular Neoplasms | 1 | 2024 | 8 | 0.220 |
Why?
|
| Clinical Competence | 2 | 2015 | 1066 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 667 | 0.210 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2023 | 25 | 0.210 |
Why?
|
| Maxillary Fractures | 1 | 2022 | 10 | 0.200 |
Why?
|
| Maxillofacial Injuries | 1 | 2022 | 9 | 0.200 |
Why?
|
| Chorionic Gonadotropin | 1 | 2023 | 79 | 0.200 |
Why?
|
| Head | 1 | 2023 | 112 | 0.190 |
Why?
|
| Male | 19 | 2024 | 65881 | 0.190 |
Why?
|
| Orbital Fractures | 1 | 2022 | 39 | 0.190 |
Why?
|
| Larynx | 1 | 2023 | 78 | 0.190 |
Why?
|
| Eye Injuries | 1 | 2022 | 52 | 0.190 |
Why?
|
| Glossectomy | 1 | 2021 | 10 | 0.190 |
Why?
|
| Metformin | 1 | 2023 | 162 | 0.180 |
Why?
|
| Female | 15 | 2024 | 71658 | 0.180 |
Why?
|
| Wounds, Gunshot | 1 | 2022 | 148 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2023 | 186 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 168 | 0.180 |
Why?
|
| Mechanical Thrombolysis | 1 | 2020 | 10 | 0.180 |
Why?
|
| Pharyngeal Diseases | 1 | 2020 | 20 | 0.170 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 23 | 0.170 |
Why?
|
| Papillomaviridae | 2 | 2022 | 189 | 0.170 |
Why?
|
| Survival Rate | 3 | 2020 | 2207 | 0.160 |
Why?
|
| Risk | 1 | 2021 | 831 | 0.160 |
Why?
|
| Adult | 8 | 2024 | 31946 | 0.150 |
Why?
|
| Gastrostomy | 1 | 2019 | 92 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 1315 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2021 | 474 | 0.150 |
Why?
|
| Length of Stay | 1 | 2024 | 1383 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2021 | 816 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2019 | 3695 | 0.140 |
Why?
|
| Microvessels | 1 | 2018 | 64 | 0.140 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2017 | 11 | 0.140 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 147 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2023 | 13011 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 128 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 137 | 0.130 |
Why?
|
| Lurasidone Hydrochloride | 1 | 2016 | 3 | 0.130 |
Why?
|
| Irritable Mood | 1 | 2016 | 11 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 907 | 0.120 |
Why?
|
| Internship and Residency | 2 | 2017 | 1250 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 276 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 560 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2017 | 310 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 389 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 471 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1334 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5505 | 0.110 |
Why?
|
| Prostate | 2 | 2007 | 448 | 0.110 |
Why?
|
| Nasal Provocation Tests | 1 | 2013 | 1 | 0.100 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2013 | 8 | 0.100 |
Why?
|
| Antigens, Fungal | 1 | 2013 | 34 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 7204 | 0.100 |
Why?
|
| Autistic Disorder | 1 | 2016 | 365 | 0.100 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 388 | 0.100 |
Why?
|
| Stroke | 1 | 2020 | 1073 | 0.100 |
Why?
|
| Computational Biology | 1 | 2017 | 887 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 1789 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 569 | 0.090 |
Why?
|
| Texas | 1 | 2020 | 3689 | 0.090 |
Why?
|
| Salvage Therapy | 2 | 2023 | 202 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 2 | 2008 | 272 | 0.080 |
Why?
|
| Pregnancy | 1 | 2023 | 7523 | 0.080 |
Why?
|
| Algorithms | 1 | 2017 | 1735 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2023 | 6664 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 1814 | 0.070 |
Why?
|
| Prognosis | 4 | 2022 | 5074 | 0.070 |
Why?
|
| Iatrogenic Disease | 1 | 2007 | 136 | 0.070 |
Why?
|
| Precision Medicine | 2 | 2022 | 356 | 0.060 |
Why?
|
| Skull Base | 1 | 2024 | 54 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2024 | 244 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 307 | 0.050 |
Why?
|
| General Surgery | 1 | 2005 | 217 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 118 | 0.050 |
Why?
|
| Neck | 1 | 2022 | 143 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 3054 | 0.040 |
Why?
|
| Pharyngectomy | 1 | 2020 | 7 | 0.040 |
Why?
|
| Contrast Media | 1 | 2024 | 512 | 0.040 |
Why?
|
| Risk Factors | 4 | 2019 | 11086 | 0.040 |
Why?
|
| Glottis | 1 | 2019 | 31 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 154 | 0.040 |
Why?
|
| Deglutition | 1 | 2019 | 60 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 203 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 413 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 255 | 0.040 |
Why?
|
| Adolescent | 3 | 2023 | 20536 | 0.040 |
Why?
|
| Comorbidity | 1 | 2022 | 1614 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 232 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 275 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 399 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2017 | 198 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 544 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 714 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 258 | 0.030 |
Why?
|
| Reference Values | 1 | 2015 | 742 | 0.030 |
Why?
|
| United States | 2 | 2019 | 11683 | 0.030 |
Why?
|
| Alternaria | 1 | 2013 | 4 | 0.030 |
Why?
|
| Aspergillus | 1 | 2013 | 27 | 0.030 |
Why?
|
| Rhinitis, Allergic | 1 | 2013 | 15 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 559 | 0.020 |
Why?
|
| Skin Tests | 1 | 2013 | 83 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1337 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3849 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1489 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1977 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 615 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1909 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3640 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 560 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 3751 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3739 | 0.020 |
Why?
|
| Young Adult | 1 | 2022 | 9887 | 0.020 |
Why?
|
| California | 1 | 2008 | 142 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2007 | 33 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 5173 | 0.020 |
Why?
|
| Disease Progression | 1 | 2007 | 2239 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 18911 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 1720 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 36398 | 0.010 |
Why?
|
| Child | 1 | 2016 | 25739 | 0.010 |
Why?
|